Hitting the Bullseye With Anti-BCMA Treatment – An In The Clinic Activity

This CME activity was created prior to the voluntary withdrawal of the FDA indication for belantamab mafodotin by the manufacturer. The data contained within were current at the time of publication.





This educational activity is provided by Integrity Continuing Education, Inc.


This educational activity is supported by an educational grant from GlaxoSmithKline.


Although the survival of patients with multiple myeloma (MM) has drastically improved over the last two decades due to advances in treatment, the disease remains incurable and patients relapse several times. These patients may be relapsed or refractory (RR) to multiple lines of therapy. A relatively new class of agents that target B-cell maturation antigen (BCMA), which is highly expressed on the surface of myeloma cells, has made significant progress.

Currently, there are 3 BCMA-directed therapies for RRMM: one antibody drug conjugate (ADC) and two chimeric antigen-receptor T cell (CAR T) agents. Each offers distinct advantages and benefits. The ADC is an “off the shelf” treatment option that does not require collection and manufacturing, which can be advantageous for patients that have aggressive disease or that cannot tolerate the pretreatment conditioning. Both CAR T agents utilize a collection and manufacturing process that can take several weeks, even if the facility is available immediately. Patients may require bridging therapy during the interim.

While these new treatments offer more options for this group of patients, treatment selection can be challenging, necessitating consideration of: disease-related and patient-related factors, such as disease morbidity (eg, refractory disease, renal impairment, extramedullary disease, or aggressiveness of disease in general), age and frailty (eg, performance status, disability), comorbidities, and cytogenetics.

This activity will provide insight and guidance from the experts in multiple myeloma and will address the challenges experienced in clinical practice.


Ola Landgren, MD, PhD
Chief of Myeloma
Professor of Medicine
Department of Medicine/Hematology
Sylvester Comprehensive Cancer Center
University of Miami
Miami, Florida


Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia


Nisha Joseph, MD
Assistant Professor
Department of Hematology and Medical Oncology
Winship Cancer Institute, Emory University
Atlanta, Georgia


Release date: September 29, 2022
Expiration date: September 29, 2023
Estimated time to complete activity: 60 minutes



This educational activity has been designed to meet the needs of hematologist oncologists, medical oncologists, and other healthcare providers who treat and manage patients with relapsed/refractory multiple myeloma.


Upon completion of this educational activity, participants should be able to:

  • Assess patients and select appropriate therapy based upon patient (comorbid conditions, proximity to treatment center, personal preferences) and disease characteristics (aggressiveness, stage, etc)
  • Incorporate multidisciplinary strategies to provide optimal care and management of treatment-related side effects

There are no fees for participating and receiving CME credit for this activity. During the period of September 29, 2022 through September 29, 2023, participants must:

  • Read the learning objectives
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.




Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Ola Landgren, MD, PhD
Advisory Boards: Adaptive Biotech, Amgen, Bristol Myers Squibb, Janssen, Pfizer
Grant Support: Amgen, Janssen, Karyopharm, Takeda
IDMC: Amgen, Janssen, Takeda

Sagar Lonial, MD, FACP
Advisory Board: TG Therapeutics
Consultant: AbbVie, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Novartis, Takeda
Research Support: Bristol Myers Squibb, Celgene, Janssen, Takeda

Nisha Joseph, MD has no real or apparent conflicts of interest to disclose.

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest